Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript
…
0,768€
0,13%
Echtzeit-Aktienkurs Seres Therapeutics
Bid:
Ask:
Nachrichten zur Seres Therapeutics Aktie
Seres Therapeutics chief legal officer sells $2,939 in stock By Investing.com
Seres Therapeutics chief legal officer sells $2,939 in stock…
Seres Therapeutics executive sells shares worth $2,058 By Investing.com
Seres Therapeutics executive sells shares worth $2,058…
Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript
…
Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024
CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today…
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass, June 07, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a…
Seres Therapeutics executive sells shares worth $882 By Investing.com
Seres Therapeutics executive sells shares worth $882…
Seres Therapeutics executive sells shares worth $660 By Investing.com
Seres Therapeutics executive sells shares worth $660…
Seres Therapeutics CEO sells $2,288 in stock By Investing.com
Seres Therapeutics CEO sells $2,288 in stock…
Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript
…
Seres Therapeutics stock target cut to $5, maintains Outperform rating By Investing.com
Seres Therapeutics stock target cut to $5, maintains Outperform rating…
Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript
…
Seres Therapeutics Q4 2023 Earnings Preview
…
Seres Therapeutics appoints new CFO as Arkowitz retires By Investing.com
Seres Therapeutics appoints new CFO as Arkowitz retires…
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Spero Therapeutics Inc. (NASDAQ: SPRO)
NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation…
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Seres Therapeutics, Inc. (NASDAQ: MCRB) and Encourages Investors to Contact the Firm
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Seres Therapeutics, Inc.…
Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript
…
INVESTOR ALERT: Abbott Cooper PLLC Announces Investigation into Seres Therapeutics, Inc.; Urges Seres Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Abbott Cooper PLLC Announces Investigation into Seres Therapeutics, Inc.…
Seres Therapeutics (MCRB) Misses Q2 Earnings Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -34.55% and 0.78%, respectively, for the quarter ended June 2023. Do…
Form 8-K Seres Therapeutics, Inc. For: Aug 08
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Seres Therapeutics Q2 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Seres Therapeutics, Inc. For: Jun 22
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 10-Q Seres Therapeutics, Inc. For: Mar 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Seres Therapeutics GAAP EPS of -$0.57 misses by $0.02
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Seres Therapeutics Q1 2023 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
FDA approves the manufacture of new microbiome-based therapeutic VOWST™ at Recipharm site
Recipharm, a global contract development and manufacturing organization (CDMO), has announced today that its subsidiary, GenIbet Biopharmaceuticals, has been approved…
Insiderhandel: Vorstand verkauft Aktien von Seres Therapeutics im Wert von 36.527$
Ege, David S. - Vorstand - Tag der Transaktion: 2023-04-28...…
Seres Therapeutics Shares Drop 15% After FDA Approval of Vowst, Debt Financing
Seres Therapeutics Shares Drop 15% After FDA Approval of Vowst, Debt Financing...…
Seres Therapeutics started at JP Morgan at neutral on c. difficile candidate
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Seres Therapeutics started at neutral with $7 stock price target at J.P. Morgan
Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…
Strength Seen in Seres Therapeutics (MCRB): Can Its 5.8% Jump Turn into More Strength?
Seres Therapeutics (MCRB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions…
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
Arrowhead Pharmaceuticals and Seres Therapeutics are screaming buys, according to some Wall Street analysts....…
Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?
Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest…
Seres Therapeutics falls 9% on full-year earnings miss
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Seres Therapeutics (MCRB) Reports Q4 Loss, Misses Revenue Estimates
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -31.71% and 89.21%, respectively, for the quarter ended December 2022. Do…
Form 10-K Seres Therapeutics, Inc. For: Dec 31
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Seres Therapeutics, Inc. For: Mar 07
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…
Seres Therapeutics FY 2022 Earnings Preview
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Form 8-K Seres Therapeutics, Inc. For: Jan 09
Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…